The OncLive® Global Oncology condition center page is a comprehensive resource for clinical news and international expert insights on treatment of patients with cancer. This page features articles focused on ex-US regulatory news, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing global research in oncology care.
Oxidative Stress, Antioxidant Status Remain High in Nigerian Patients With Prostate Cancer
December 4th 2020Nigerian patients with prostate cancer are noted as having higher levels of total plasma peroxide, malondialdehyde, and nitric oxide, as well as lower levels of total antioxidant capacity, even while undergoing androgen-deprivation therapy compared with Nigerian men who don't have prostate cancer.
Read More
Regulatory applications have been submitted to the FDA and the European Medicines Agency for subcutaneous daratumumab for use in combination with pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma who have received at least 1 previous therapy.
Read More
Enzalutamide Approved in China for Nonmetastatic Castration-Resistant Prostate Cancer
November 11th 2020November 10, 2020 - The China National Medical Products Administration has approved enzalutamide for the treatment of adult patients with nonmetastatic castration-resistant prostate cancer who are at a higher risk of metastasis.
Read More
Nivolumab/Ipilimumab Plus Chemo Approved in Europe for Frontline Metastatic NSCLC
November 6th 2020The European Commission has approved the combination of nivolumab plus ipilimumab with 2 cycles of platinum-based chemotherapy for the up-front treatment of adult patients with metastatic non–small cell lung cancer without a sensitizing EGFR mutation or an ALK translocation.
Read More
Olaparib/Bevacizumab Approved in Europe for Frontline Maintenance in HRD+ Advanced Ovarian Cancer
November 5th 2020The European Union has approved olaparib in combination with bevacizumab for use as a first-line maintenance treatment in patients with homologous recombination deficient–positive advanced ovarian cancer.
Read More
Atezolizumab/Bevacizumab Approved in Europe for Advanced or Unresectable HCC
November 2nd 2020The European Commission has approved the combination of atezolizumab plus bevacizumab for use in adult patients with advanced or unresectable hepatocellular carcinoma who have not been given previous systemic therapy.
Read More
Atezolizumab Plus Bevacizumab Approved in China for Hepatocellular Carcinoma
October 30th 2020The China National Medical Products Administration has approved the combination of atezolizumab plus bevacizumab for use in patients with unresectable hepatocellular carcinoma who have not received previous systemic therapy.
Read More
Niraparib Approved in Europe for Frontline Maintenance in Advanced Ovarian Cancer
October 29th 2020The European Commission has approved niraparib for use as a frontline monotherapy maintenance option in adult patients with advanced epithelial, high-grade ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response after platinum-based chemotherapy.
Read More
Approval Sought for Cabozantinib/Nivolumab for Unresectable, Advanced, or Metastatic RCC in Japan
October 27th 2020A supplemental application was submitted to the Japanese Ministry of Health, Labour, and Welfare for Manufacturing and Marketing approval of the combination of cabozantinib plus nivolumab for the treatment of patients with unresectable, advanced, or metastatic renal cell carcinoma.
Read More
First-in-Human T-Cell Therapy Warrants Further Investigation in HCC
October 9th 2020New data showing efficacy and tolerability with ADP-A2AFP, alpha-fetoprotein–directed specific peptide enhanced affinity receptor T-cells, suggest that further research evaluating the 5 billion or more cell dosing regimen is warranted in hepatocellular carcinoma.
Read More
Dr. Kristeleit on QoL With Dostarlimab in dMMR/MSI-H Endometrial Cancer
September 30th 2020Rebecca Kristeleit, BSc, MBChB, MRCP, PhD, discusses the importance of patient-reported outcomes in the phase 1 GARNET trial in advanced or recurrent mismatch repair deficient/microsatelite instability-high endometrial cancer.
Watch
Dr. McDermott on Rationale for Darolutamide Plus ADT/Radiation in High-Risk Prostate Cancer
September 30th 2020Ray McDermott, MB, BCh, BAO, PhD, MBA, FRCPI, discusses the rationale for the addition of darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high-risk prostate cancer.
Watch